Form 4: Louise M. Parent Acquires 1,596 Restricted Stock Units in Zoetis Inc. (ZTS)

Director Louise M. Parent received 1,596 restricted stock units (RSUs) of Zoetis Inc. (ZTS) on February 19, 2025, which will vest on the first anniversary of the grant date.

Summary

• On February 19, 2025, Louise M. Parent, a director of Zoetis Inc., was granted 1,596 restricted stock units (RSUs).
• These RSUs were granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
• Each RSU represents the contingent right to receive one share of Zoetis Inc. common stock.
• The RSUs will vest and be settled in shares of Zoetis Inc. common stock on February 19, 2026, contingent upon continued service.
• The transaction was reported on February 20, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard equity grant, indicating confidence in the director's continued service and the company's future performance.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The director's continued service is required for the RSUs to vest, indicating an expectation of ongoing involvement with Zoetis Inc.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term performance of the company.

Comparison to Industry Standards

• Zoetis' equity compensation practices are likely in line with industry standards for companies of its size and market capitalization.
• Comparable companies in the animal health sector, such as Elanco and Merck Animal Health, also utilize equity-based compensation to incentivize their executives and directors.

Stakeholder Impact

• The grant of RSUs aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates